Seagen reports fourth quarter and full year 2022 financial results

Bothell, wash.--(business wire)--seagen inc. (nasdaq:sgen) today reported financial results for the fourth quarter and year ended december 31, 2022. the company also highlighted padcev® (enfortumab vedotin-ejfv), tukysa® (tucatinib), adcetris® (brentuximab vedotin) and tivdak® (tisotumab vedotin-tftv) commercial and development accomplishments, as well as progress across its potentially transformative oncology pipeline.
SGEN Ratings Summary
SGEN Quant Ranking